Prihlásiť sa Zaregistrujte sa zadarmo

Vydané akcie spoločnosti Theratechnologies

Aká je hodnota metriky Vydané akcie spoločnosti Theratechnologies?

Hodnota metriky Vydané akcie spoločnosti Theratechnologies Inc. je 45.981M

Aká je definícia metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všetkých akcií spoločnosti alebo finančných aktív, ktoré boli autorizované, vydané a kúpené investormi a sú nimi vlastnené.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Theratechnologies

Čomu sa venuje spoločnosť Theratechnologies?

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.

Firmy s metrikou vydané akcie podobnou spoločnosti Theratechnologies